217 related articles for article (PubMed ID: 36905443)
1. The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
Pinar U; Calleris G; Grobet-Jeandin E; Grande P; Benamran D; Thibault C; Gontero P; Rouprêt M; Seisen T
World J Urol; 2023 Nov; 41(11):3205-3230. PubMed ID: 36905443
[TBL] [Abstract][Full Text] [Related]
2. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review.
Peyronnet B; Seisen T; Dominguez-Escrig JL; Bruins HM; Yuan CY; Lam T; Maclennan S; N'dow J; Babjuk M; Comperat E; Zigeuner R; Sylvester RJ; Burger M; Mostafid H; van Rhijn BWG; Gontero P; Palou J; Shariat SF; Roupret M
Eur Urol Focus; 2019 Mar; 5(2):205-223. PubMed ID: 29154042
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
4. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.
Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E;
World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261
[TBL] [Abstract][Full Text] [Related]
6. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.
Dominguez-Escrig JL; Peyronnet B; Seisen T; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Gontero P; Lam T; MacLennan S; Mostafid H; Palou J; van Rhijn BWG; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M
Eur Urol Focus; 2019 Mar; 5(2):224-241. PubMed ID: 29158169
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
[TBL] [Abstract][Full Text] [Related]
8. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
Lee KS; Kim KH; Yoon YE; Choi KH; Yang SC; Han WK
Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
Seisen T; Peyronnet B; Dominguez-Escrig JL; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Cowan NC; Kaasinen E; Palou J; van Rhijn BW; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M
Eur Urol; 2016 Dec; 70(6):1052-1068. PubMed ID: 27477528
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs.
Del Giudice F; van Uem S; Li S; Vilson FL; Sciarra A; Salciccia S; Busetto GM; Maggi M; Tiberia L; Viscuso P; Canale V; Panebianco V; Pecoraro M; Ferro M; Moschini M; Krajewski W; D'Andrea D; Cacciamani GE; Mari A; Soria F; Porpiglia F; Fiori C; Amparore D; Checcucci E; Autorino R; De Berardinis E; Chung BI
Clin Genitourin Cancer; 2022 Apr; 20(2):198.e1-198.e9. PubMed ID: 35031226
[TBL] [Abstract][Full Text] [Related]
13. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
Li H; Zhou J; Chen R; Zhu J; Wang J; Wen R
Urol Oncol; 2023 Aug; 41(8):356.e1-356.e9. PubMed ID: 37331821
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis.
Yuan H; Chen X; Liu L; Yang L; Pu C; Li J; Bai Y; Han P; Wei Q
Urol Oncol; 2014 Oct; 32(7):989-1002. PubMed ID: 25082191
[TBL] [Abstract][Full Text] [Related]
17. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
[TBL] [Abstract][Full Text] [Related]
18. Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
Veeratterapillay R; Geraghty R; Pandian R; Roy C; Stenhouse G; Bird C; Soomro N; Paez E; Rogers A; Johnson M; Page T; Rix D; Thomas D; Rai BP
BJU Int; 2022 Jun; 129(6):744-751. PubMed ID: 34726325
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.
Matsunaga T; Komura K; Hashimoto T; Muraoka R; Satake N; Tsutsumi T; Tsujino T; Yoshikawa Y; Takai T; Minami K; Taniguchi K; Tanaka T; Uehara H; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Ohno Y; Azuma H
World J Urol; 2020 Dec; 38(12):3183-3190. PubMed ID: 32065276
[TBL] [Abstract][Full Text] [Related]
20. The characteristics of recurrent upper tract urothelial carcinoma after radical nephroureterectomy without bladder cuff excision.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Yonsei Med J; 2015 Mar; 56(2):375-81. PubMed ID: 25683984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
